Alişan Kayabölen

Dr. Alişan Kayabölen holds a bachelor’s degree from Molecular Biology and Genetics in Middle East Technical University (METU). He did his master’s study on “development of vascularized adipose tissue using stem cells and hydrogels” in Biomedical Engineering, METU. He holds a PhD degree from Koç University, Cellular and Molecular Medicine. During his doctoral study, under Dr. Tuğba Bağcı-Önder’s supervision, he investigated “effects of IDH mutations on brain tumor development, and response of IDH-mutant glioma to epigenetic-based therapeutic approaches”. He also studied on development of CRISPR-based gene knock-out libraries, and gene activation/repression systems to be used for sensitization of drug-resistant brain tumor cells. During his undergraduate and graduate years, Dr. Kayabölen was supported by TÜBİTAK BİDEB as a continuous scholar. As 2020, he works as a post-doctoral researcher in KUTTAM, Koç University.



  • Ozyerli-Goknar E, Sur-Erdem I, Seker F, Cingöz A, Kayabolen A, Kahya Z, Uyulur F, Gezen M, Erman B, Gonen M, Oppermann U, Bagci-Onder T. “The fungal metabolite chaetocin is a sensitizer for pro-apoptotic therapies in glioblastoma”. Cell Death Dis., 10 (12), 894. Nov 26, 2019.
  • Kaya-Aksoy E, Cingoz A, Senbabaoglu F, Seker F, Sur-Erdem I, Kayabolen A, Lokumcu T, Sahin GN, Karahuseyinoglu S, Bagci-Onder T. “The pro-apoptotic Bcl-2 family member Harakiri (HRK) induces cell death in glioblastoma multiforme”. Cell Death Discovery (2019) 5:64.
  • Kayabolen A, Keskin D, Aykan A, Karslıoglu Y, Zor F, Tezcaner A. “Native extracellular matrix/fibroin hydrogels for adipose tissue engineering with enhanced vascularization.” Biomedical Materials 2017; 12(3), 035007.
  • Yaprakci V, Erdemli O, Kayabolen A, Tezcaner A, Bozkurt F, Keskin D. “In vitro/In vivo comparison of cefuroxime release from polycaprolactone (PCL)/Calcium sulfate (CaS) implants for osteomyelitis treatment. Biotechnol Appl Biochem. 2013 Nov-Dec;60(6):603-16.